Enfortumab Vedotin Impresses In Urothelial Cancer After Chemo, Immunotherapies

 
• By John Davis

The antibody-drug conjugate being evaluated by Astellas and Seattle Genetics has posted “remarkable” positive top-line results in locally advanced or metastatic urothelial cancer, with a US BLA submission expected later in 2019.  

Goalpost
The goal of a better therapy for urothelial cancer may be within reach. • Source: Shutterstock

More from Anticancer

More from Therapy Areas